Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the Centers for Disease Control and Prevention, announced the decision on May 27 and said vaccine guidance would now focus solely on adults over 65 and those with high-risk conditions, effective immediately. By June 3, Dr. Lakshmi Panagiotakopoulos stepped down from her role helping lead the agency's COVID-19 vaccine advisory group, saying she could no longer support decisions that put pregnant people and children at risk.
Before the changes took effect, COVID-19 vaccines were recommended for anyone 6 months and older. Kennedy did not offer a scientific rationale for the new recommendations.
For Black Americans, the policy shifts are more than bureaucratic changes, according to Oni Blackstock, a physician and founder of Health Justice, a racial and health equity consulting practice.
'These new guidelines don't exist in a vacuum,' she said. 'Limiting booster eligibility risks further compromising the already fragile health status of many Black Americans.'
Black Americans are 1.5 times more likely to contract COVID-19 and four times more likely to be hospitalized, according to the Centers for Medicare & Medicaid Services. Research from the Center for Primary Care at Harvard Medical School found that Black children are more than five times as likely to die from the virus. An estimated 165,000 to 220,000 Black Americans have died from COVID-19, according to data compiled by the APM Research Lab.
According to a 2023 report from the U.S. Census Bureau, nearly 32% of Black Americans who contracted COVID-19 also experienced long COVID symptoms.
The U.S. Food and Drug Administration cited a lack of evidence that annual boosters are needed by healthy, low-risk adults. However, Blackstock, a primary care and HIV physician, said the policy change marks a significant departure from past years when vaccines were broadly recommended and federally funded.
'This contradicts recent CDC data showing that the 2024–2025 boosters benefit people 18 years and older, especially early after vaccination,' she added.
Blackstock noted that many Black Americans already struggle with health care access due to systemic barriers like a lack of insurance and residential segregation.
'When these combine with more restrictive vaccine guidelines,' she said, 'it becomes even harder for Black Americans to get boosters and worsens existing health disparities.'
These barriers also deepen historic mistrust in health care, said Jerry Abraham, a family and community medicine physician. Abraham, who is director of the CDU-KEDREN Mobile Street Medicine program in Los Angeles, said the history of medical racism and continued treatment disparities fuel skepticism toward public health. Even as boosters offer real benefits, he said, many remain hesitant or disconnected from resources that ensure protection.
'If children and pregnant women are no longer recommended for vaccination, will grandma still go to CVS and get it herself?' he said.
Abraham added that in an era where health care professionals can no longer trust the updated guidelines from federal agencies, it's deeply concerning and a reminder that Black communities must once again rely on themselves.
For answers about what comes next, read on.
Aisha Harris, a family medicine physician in Flint, Michigan, told Capital B that limiting access to COVID-19 vaccines for healthy adults exposes high-risk groups like seniors and those who are immunocompromised.
'Reduced protection in healthy people increases their risk of being infected by COVID and of being a carrier,' said Harris, who owns the direct primary care clinic Harris Family Medicine. 'When more people are contagious, with or without symptoms, they have a higher chance of infecting others around them, including in their household or those they are taking care of as caregivers.'
She warned this undermines community immunity. Without widespread coverage, even eligible groups face elevated risks.
FDA officials say the new approach mirrors those taken by Australia and several European nations that limit vaccines to older or high-risk adults. But some critics argue the shift ignores U.S. disparities and bypasses standard CDC procedures.
You can pay out of pocket, but it could cost up to $200. If the CDC doesn't recommend vaccines, Abraham said health plans are much less likely to cover them, since insurers typically follow CDC guidance.
Yes, COVID-19 vaccines have already undergone extensive clinical trials before being authorized for public use.
The FDA says it will require longer clinical trials before approving updated shots for healthy kids and adults, with studies lasting at least six months, likely delaying fall approvals.
The CDC's vaccine advisory committee is expected to vote on fall vaccine recommendations in late June, but it's unclear how much influence it will have over the newly announced changes.
High-risk conditions for COVID-19 vaccine eligibility generally include chronic kidney disease, chronic lung diseases, asthma, diabetes, immunocompromised states (from cancer treatment, organ transplant, HIV, etc.), heart conditions, Alzheimer's disease, obesity, sickle cell disease, smoking, and stroke or cerebrovascular disease.
Yes. Studies show COVID-19 vaccination, including boosters, reduces the risk of severe illness and may lower the chances of developing long COVID symptoms after infection.
The post Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut. appeared first on Capital B News.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Boston Globe
32 minutes ago
- Boston Globe
First pill for postpartum depression shows varied real-world results
'I felt like I wasn't doing enough, I wasn't doing anything right,' she said. She began to think her son and husband might be better off without her. When the baby was about 5 months old, she tried to take her life with a gun. Cohn, 30, who lives near Fayetteville, North Carolina, was hospitalized for weeks and underwent surgeries to repair damage to her jaw, nose, tongue and face. But her postpartum depression remained challenging to treat. The hospital's maternal mental health specialists decided to have her try a medication that had recently become available: the first pill specifically for postpartum depression. Clinical trials had found that the drug, zuranolone, marketed as Zurzuvae and taken daily for 14 days, can ease symptoms for some women in as little as three days, while general antidepressants can take weeks. For Cohn, its impact was swift and striking. On her fourth day of taking it, she said she suddenly 'felt so much clarity in my head, like I didn't have nagging thoughts about not being good enough.' Advertisement Now, a year and a half after the drug became available, thousands of women have tried it, and their experiences have run the gamut. For some, symptoms improved remarkably. Others described a modest benefit that didn't last or said their depression persisted. And others didn't complete the two-week regimen because profound drowsiness, a common side effect of the drug, interfered with their ability to care for their babies or to fulfill other responsibilities. Advertisement One in eight women in the United States experiences depression during pregnancy or in the year after giving birth, the Centers for Disease Control and Prevention estimates, and effective treatments are crucially needed. While the fast-acting pill shows promise, doctors say the challenge now is to determine which patients will benefit and why some don't. Clinical trials of the drug found that postpartum depression improved in about 60% of patients. 'It's not everyone,' Dr. Samantha Meltzer-Brody, a leader of the trials and director of the Center for Women's Mood Disorders at the University of North Carolina at Chapel Hill, said at a National Institutes of Health conference. 'So, what is it about the people that are going to respond versus those that don't?' Stacey, 42, of San Diego, who asked to be identified only by her first name to protect her privacy, said Zurzuvae made her 'so tired' that after several days of taking it, 'I just felt like a zombie.' 'I actually felt more depressed while I was on it,' she said. To address Stacey's response to the medication, Dr. Alison Reminick, director of women's reproductive mental health at the University of California, San Diego, advised her to take half doses for the rest of the 14 days. But Stacey said she stopped Zurzuvae altogether, halfway through the regimen, because the sluggishness made it difficult to care for her baby. Advertisement 'The medication is incredibly sedating,' Reminick said. 'There's a warning on the box. They can't drive for 12 hours after taking it, and they can't really take care of their children without help.' Yet, some patients don't experience sedation and others welcome it because it helps them get much-needed sleep and feel less overwhelmed, said doctors who prescribe Zurzuvae. The week after Cohn started taking Zurzuvae, the turnaround of her symptoms was so obvious that she was discharged from the hospital. 'She had a really nice improvement of her postpartum depression with that medicine,' said Dr. Riah Patterson, a psychiatrist at the University of North Carolina Chapel Hill. Cohn finished the 14-day regimen at home and attended intensive outpatient therapy for months. Now, she has gone back to work as a tattoo artist, and she said that with weekly therapy and an anxiety medication, she is managing the aftermath of the crisis, including undergoing additional surgeries. 'I'm just excited to get a little bit closer to really being me again,' she said. She no longer feels anxious about her parenting ability and enjoys playing with her son and taking him to places like the local children's museum. 'He makes everything worth pushing through.' An ultrasound of Samantha Cohn's pregnancy on her refrigerator, near Fayetteville. The drug zuranolone relieved Cohn's postpartum depression, which was so severe that she tried to take her own life. MADELINE GRAY/NYT Importance of Quick Intervention Zurzuvae is a synthetic version of a steroid called allopregnanolone that originates in the brain. The theory behind the medication is that perinatal depression often arises as hormones that surge in pregnancy plummet during childbirth. Some patients seem particularly sensitive to that sudden drop-off, which also lowers levels of the steroid, Meltzer-Brody said. Zurzuvae can be taken with other antidepressants, and, since it is prescribed for only a single 14-day course, some doctors use it as an adjunct or bridge to ease severe symptoms before longer-term use of antidepressants. Advertisement Some patients who are breastfeeding have declined to take the drug because its penetration of breast milk has not yet been studied. Doctors said it is most likely safe, but if patients are concerned, they might pump two weeks' worth of milk before starting Zurzuvae. Initial logistical hurdles in obtaining Zurzuvae frustrated doctors who said the delays undermined the purpose of a quick-acting medication. Some insurers initially set strict conditions for covering the drug, which has a list price of $15,900. Doctors said some insurers required patients to try other antidepressants first or to obtain prescriptions from psychiatrists, steps that went beyond the FDA requirements for Zurzuvae. Joy Burkhard, CEO of the Policy Center for Maternal Mental Health, said most insurers and Medicaid no longer have such barriers, but a few still require extra steps. Zurzuvae is not available in retail pharmacies, only specialty pharmacies that require patients to take various measures to validate insurance and delivery information, according to a spokesperson for Chris Benecchi, chief operating officer of Sage, which is expected to be acquired by Supernus Pharmaceuticals later this year, said Sage had worked to resolve logistical issues and that prescriptions had increased. More than 10,000 orders have been sent to patients, Sage said, adding that about 80% of the prescriptions were issued by OB-GYNs. 'The majority of patients are able to get the medication within days,' Benecchi said, adding that if patients encounter delays, Sage will ship Zurzuvae directly 'as rapidly as possible.' Advertisement Quick access is crucial, doctors say. Hannah Ginther was hospitalized for a week last summer at UNC Chapel Hill for symptoms that included obsessively worrying that her second child, then 10 months old, had a neurological disorder, even though doctors said the baby did not. 'I just couldn't get out of that loop of jumping to worst-case-scenario,' Ginther, 36, said at her home in Wilmington, North Carolina. 'I would throw up. I struggled to get out of bed, struggled to do basic, daily-living things.' When she was discharged from the hospital, doctors prescribed Zurzuvae, but her insurance rejected coverage, saying she would qualify only if she had developed postpartum depression in her last trimester of pregnancy, or within four weeks after childbirth, Patterson said. Ultimately, the hospital appealed to Sage, which sent the drug to Ginther at no cost. But the insurance hiccups had caused a two-week delay, during which, Ginther said, her symptoms 'spiraled again.' She was rehospitalized for nine days. Dr. Julia Riddle, a psychiatrist at UNC Chapel Hill, said the second hospitalization might have been avoided if the Zurzuvae had arrived sooner. In clinical trials, patients helped by Zurzuvae continued doing well 45 days later. About half of those who took Zurzuvae were considered to be in remission. Riddle is following patients to see if the benefit can last longer. 'No one's illness is exactly the same,' Riddle said. So far 'no one has said they'd never take it again; it's just varying levels of how helpful it was.' Advertisement This article originally appeared in .

Miami Herald
2 hours ago
- Miami Herald
Covid-19 drug company liquidates assets in Chapter 11 bankruptcy
When the Covid-19 public health crisis began in the U.S. with the first confirmed case of the 2019 Novel Coronavirus in Washington state on Jan. 20, 2020, the terrifying pandemic was underway, and the Centers for Disease Control and Prevention would report its first confirmed death from the virus on Feb. 29. By March 3, 2020, CDC reported 60 confirmed cases in 12 states. On March 13, the first Trump administration declared a national emergency, and states started implementing shutdowns on March 15, according to the CDC's timeline of Covid-19 events. Don't miss the move: Subscribe to TheStreet's free daily newsletter Biotechnology firms Pfizer-BioTech and Moderna Therapeutics began developing Covid-19 vaccines in March 2020, and by November 2020, each company's Covid-19 vaccine would be found 95% effective in clinical trials. Related: CVS rival pharmacy chain files for Chapter 11 bankruptcy Another biotech firm, Regeneron, in November received approval of an antibody treatment to significantly reduce virus levels within days. In December 2020, Covid-19 vaccinations began, and by Dec. 24, 1 million people had been vaccinated in the U.S. CDC said that by June 1, 2022, the U.S. reported over 84 million Covid-19 infections and over 1 million deaths. About a year later, Pfizer reported on its website that on May 5, 2023, the World Health Organization declared an end to the Covid-19 public health emergency, while the U.S. Department of Health & Human Services did the same on May 11, 2023. The healthcare industry's response to the Covid-19 pandemic was so effective that beginning on May 1, 2024, hospitals were no longer required to report Covid-19 hospital admissions, hospital capacity, or hospital occupancy data to the U.S. Department of Health & Human Services through the Centers for Disease Control and Prevention's National Healthcare Safety Network, according to the CDC website. The end of the crisis also ended the need for massive amounts of Covid-19 drugs. With the Covid-19 pandemic subsiding, companies that stepped forward to develop vaccines, drugs, and treatments during the crisis are now facing declining demand for their services to develop Covid-19 products. With no dire need for Covid-19 products, some drug companies have been forced to downsize or even shut down operations because of a lack of business opportunities. Essential drug manufacturer Aluchua Government Services Inc., which developed Covid-19 therapy drugs under U.S. government contracts, has filed for Chapter 11 bankruptcy with plans to wind down operations and sell its assets. Related: Giant healthcare company files Chapter 11 bankruptcy seeking sale The Aluchua, Fla.-based pharmaceutical company filed its petition in the U.S Bankruptcy Court for the District of Delaware, listing $50 million in assets and $100 million to $500 million in liabilities. The debtor's largest creditors include United States International Development Finance Corp., owed $246 million; Defense Contract Management Agency, owed $11.95 million; and Sigma-Aldrich Inc. $1.33 million. Aluchua was founded in 1999 to develop new drugs and to increase efficacy of existing ones. In 2013, it was awarded a greenfield contract with the U.S. Department of Defense, and in February 2020, it was awarded a contract to develop an advanced monoclonal antibody therapy against Covid-19 infection. The Covid-19 drug was one of several that the debtor partnered with the U.S. government to develop and produce drugs, vaccines, and treatments. The debtor needed to file for Chapter 11 protection after demand for its services began to decline in late 2023 and certain government contracts were wound down or scaled back, according to Aluchua's Chief Restructuring Officer Janet R. Naifeh of FTI Consulting Inc. Aluchua's efforts to replace its government business with commercial contracts failed, which forced it to scale down production and lay off 125 employees from January through April 2025. It reduced its staff by another 67 employees on June 20 and July 1, which, combined with the earlier layoffs, amounted to termination of 80% of its workforce. The company employed 13 full-time and three temporary workers as of the petition date. The company marketed itself for sale beginning in February 2025, but was unable to complete a transaction and decided its only viable option was to file for Chapter 11 bankruptcy, wind down its business, and sell its assets. Related: Iconic retail chain closing its remaining stores in bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
2 hours ago
- Yahoo
Summer Covid cases are rising across the U.S. — Is it time for a vaccine?
As Covid cases begin to rise this summer, many may be wondering: What are my risks, and is it time to get another vaccine? As of July 15, Covid cases were growing or likely growing in 27 states including Texas, Illinois, Kentucky, Virginia and Ohio, according to the Centers for Disease Control and Prevention. Rates of positive Covid tests have also been increasing in recent weeks, the CDC says, specifically in the southern region of the country. N.B.1.8.1 is the current dominant variant in the United States, accounting for 43% of all new Covid cases, according to the CDC. It's an offshoot of the XVD.1.5.1 strain, a descendant of the omicron variant. N.B.1.8.1 was responsible for a surge in hospitalizations in China earlier this year. It's been nicknamed 'razor blade throat,' as there have been anecdotal reports of some people getting painful sore throats, said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee. Schaffner noted, however, that sore throats have been a common symptom of Covid since it first began spreading. 'I doubt the clinical spectrum of Covid has changed substantially,' Schaffner said. Do I need a Covid booster? When will the new vaccines be available? The uptick in cases comes as many Americans have likely gone a year or longer without a Covid shot. In May, the Food and Drug Administration asked drugmakers to update their Covid vaccines to target the LP.8.1 strain, a descendent of JN.1, which began spreading widely in 2023 and is another offshoot of omicron. LP.8.1 currently accounts for 31% of all new cases, per the CDC. The new shots won't be available until the fall, and are expected to be approved only for adults 65 and up and kids and adults with at least one medical condition that puts them at risk of severe illness. Healthy kids and adults who want a shot may have to find an older version or pay out of pocket. A single dose can cost as much as $140. Experts say, however, that population immunity — whether from vaccination, prior infection or both — may shield much of the public for now. 'While we don't have a lot of high level of immunity in the population right now, because it's been so long, we may have enough low level immunity to just make it a little bit harder for that virus to transmit easily from person to person,' said Andy Pekosz, an infectious disease researcher at Johns Hopkins University. Indeed, weekly hospitalization rates have remained low, suggesting that the new variant may not be leading to severe illness. The number of cases are still drastically lower than those this time last year, when the test positivity rate peaked in August at 17.9%. The 2025 season has yet to scrape 5%. Pekosz said it isn't unusual for cases to rise during the summer time, when people are likely to crowd indoors to escape the heat. However, he believes that if there is a summer surge of cases, it will be a small one. 'The variants have been around for a while and haven't caused any major surges up until date,' Pekosz said. 'So again, I'm hopeful that if we see a surge, it'll be a low level surge compared to previous years.' Dr. Ofer Levy, director of the precision vaccines program at Boston Children's Hospital, who has advised the FDA, said people who are at high risk of severe illness still may want to consider getting a Covid shot, if they can find one. High risk groups include: Older adults People with weakened immune systems Pregnant women Those with underlying health conditions, such as asthma and heart disease Getting a shot is especially important, Levy said, for those who haven't had one in over a year and whose immunity has likely waned. 'If you're in a high risk group and you're in a state where cases are rising, you may want to just get the first available appointment and get a shot to protect yourself,' he said. People at high risk can then consider getting an additional Covid shot when the updated vaccines are distributed in the fall, he said. Covid has two waves a year Schaffner, of Vanderbilt, said people in the high risk groups may also want to consider wearing a mask during indoor activities, such as the movies. Healthy adults and children may be able to wait longer before getting another shot, Levy added. 'If you're in a lower risk group, that's where things get fuzzy,' he said. 'I mean if you want a vaccine and your health care provider concurs and you can get it.' Dr. Michael Phillips, an infectious disease doctor at NYU Langone, said that he sees mostly immunocompromised and older adults test positive for the virus. For those who haven't gotten a Covid shot in years, Phillips said he doesn't think they should worry just yet. 'If you're younger, otherwise healthy, I think you're OK,' Phillips said. 'If you have underlying pulmonary disease, you know, if you're an older age group, now that's a time when you should be really talking to a doctor and saying, 'Gosh, should I be getting a booster for Covid?'' He said that the amount of positive Covid tests NYU Langone has seen has decreased 40% since February. Fatima Amaeka, a senior analyst at the Center for Outbreak Response Innovation at Johns Hopkins, said she expects the current wave to peak around September. Schaffner said to expect another wave in the late fall and winter. '[Covid] has two increases each year,' he said. 'Everyone is familiar with the winter increase that goes along with flu and RSV.' This article was originally published on Solve the daily Crossword